According to the research report titled ‘Global Oncology/Cancer Blockbuster Drugs Market Research Report 2019 – 2025’, available with MarketStudyReport, global oncology/cancer blockbuster drugs market is anticipated to amass notable gains over 2019-2025.
 

Increasing prevalence of cancer across the globe, rising adoption of advanced therapies, and growth in geriatric population are aiding the expansion of global oncology/cancer blockbuster drugs market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1868453/
 

For the unversed, cancer refers to diseases related to abnormal cell growth. It has the potential to spread to different parts of the body. The treatment for this deadly ailment requires the use of various targeted and biological drug therapies.
 

Surging awareness about the disease, and widespread availability of cancer treating drugs are augmenting industry outlook.
 

On the contrary, high cost associated with the development of new medicines, along with risk of adverse effects related to various drug therapies are likely to hamper market progression in the ensuing years.
 

The study further assesses the segments and subsegments of this industry vertical to provide clearer depiction of the size and scope of global oncology/cancer blockbuster drugs market.
 

Further, a deep dive analysis of the top 27 drugs present in the market sphere is included.  As per the report the worldwide top 27 cancer blockbuster drugs market size is expected to exceed USD 120 billion by 2025.
 

The key drugs profiled in the research report are Imbruvica  Pomalyst/Imnovid, Keytruda,  Herceptin, Avastin, Perjeta, Sprycel, Revlimid, Ibrance, Zytiga, Tagrisso, Darzalex, Xtandi, Jakafi/Jakavi, Yervoy, Alimta, MabThera/Rituxan, Gleevec/Glivec, Velcade, Tasigna, Xgeva, Afinitor/Votubia, Neulasta, Exjade Jadenu, Sandostatin, Opdivo, and Faslodex.
 

Moving on, the research document includes the profiles of the major players who are evaluated based on parameters like latest developments and business overview.
 

The key companies operating in global oncology/cancer blockbuster drugs market are Amgen, Inc., Novartis International AG, Celgene Corporation, AstraZeneca plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Eli Lilly and Company, Pfizer, Inc., Bristol Myers Squibb Pharmaceuticals Limited, and F. Hoffmann-La Roche AG.